An Antigen-specific Pathway for CD8 T Cells Across the Blood-brain Barrier
Overview
General Medicine
Authors
Affiliations
CD8 T cells are nature's foremost defense in encephalitis and brain tumors. Antigen-specific CD8 T cells need to enter the brain to exert their beneficial effects. On the other hand, traffic of CD8 T cells specific for neural antigen may trigger autoimmune diseases like multiple sclerosis. T cell traffic into the central nervous system is thought to occur when activated T cells cross the blood-brain barrier (BBB) regardless of their antigen specificity, but studies have focused on CD4 T cells. Here, we show that selective traffic of antigen-specific CD8 T cells into the brain occurs in vivo and is dependent on luminal expression of major histocompatibility complex (MHC) class I by cerebral endothelium. After intracerebral antigen injection, using a minimally invasive technique, transgenic CD8 T cells only infiltrated the brain when and where their cognate antigen was present. This was independent of antigen presentation by perivascular macrophages. Marked reduction of antigen-specific CD8 T cell infiltration was observed after intravenous injection of blocking anti-MHC class I antibody. These results expose a hitherto unappreciated route by which CD8 T cells home onto their cognate antigen behind the BBB: luminal MHC class I antigen presentation by cerebral endothelium to circulating CD8 T cells. This has implications for a variety of diseases in which antigen-specific CD8 T cell traffic into the brain is a beneficial or deleterious feature.
Gordon K, Perez C, Garmilla A, Lam M, Aw J, Datta A J Immunother Cancer. 2025; 13(2).
PMID: 39933837 PMC: 11815465. DOI: 10.1136/jitc-2024-009574.
CD8 T cells exacerbate AD-like symptoms in mouse model of amyloidosis.
Wang X, Campbell B, Bodogai M, McDevitt R, Patrikeev A, Gusev F Brain Behav Immun. 2024; 122:444-455.
PMID: 39191349 PMC: 11409913. DOI: 10.1016/j.bbi.2024.08.045.
Taranov A, Bedolla A, Iwasawa E, Brown F, Baumgartner S, Fugate E Proc Natl Acad Sci U S A. 2024; 121(28):e2400213121.
PMID: 38954546 PMC: 11252789. DOI: 10.1073/pnas.2400213121.
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R JTO Clin Res Rep. 2024; 5(4):100655.
PMID: 38706978 PMC: 11069015. DOI: 10.1016/j.jtocrr.2024.100655.
Reprogramming T cells as an emerging treatment to slow human age-related decline in health.
Peplow P Front Med Technol. 2024; 6:1384648.
PMID: 38666066 PMC: 11043517. DOI: 10.3389/fmedt.2024.1384648.